PDPN 与 GD2 双靶向增强 CAR-T 细胞对胶质母细胞瘤的疗效并促进持久肿瘤控制

Dual targeting of PDPN and GD2 enhances CAR T cell efficacy against glioblastoma and promotes durable tumor control.

FECH：影响 CAR-T 细胞表型与功能的新型代谢靶点

FECH, a novel metabolic target influencing CAR T-cell phenotype and function.

儿童脑肿瘤的局部区域和全身过继性细胞疗法：CAR-T、TCR 工程 T 细胞和 NK 细胞策略的系统综述

Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell st

面向实体瘤的工程化 CAR-T 细胞：通过整合设计与临床转化克服微环境

Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical translation.

免疫基因组图谱揭示儿童脑肿瘤的基因治疗靶点

Immunogenomic profiling reveals targets for gene therapy in pediatric brain tumors.

这种整合分析方法识别出 pDMG 中可靶向的通路、表面抗原和新抗原，支持 CAR-T 和 TCR-T 疗法的开发。这些发现还提示其可能适用于其他携带相同突变的癌症。

CAR-T 细胞治疗儿童脑肿瘤：附临床试验入组标准比较分析的叙述性综述

CAR T-cell therapy in pediatric brain tumors: a narrative review with comparative analysis of clinical trial eligibility criteria.

抗 CAR 免疫驱动弥漫性中线胶质瘤对 GD2-CAR-T 细胞治疗的获得性耐药

Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma.

胶质母细胞瘤的代谢与翻译后脆弱性：二硫死亡、糖基化及对 CAR-T 治疗的启示

Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.

儿童和年轻成人原发性中枢神经系统肿瘤的 CAR-T 细胞疗法：早期临床试验的系统综述，重点关注弥漫性中线胶质瘤

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clini

初步临床经验表明，针对儿童和年轻成人 CNS 肿瘤的 CAR-T 细胞疗法具有生物学活性且临床可行，其毒性特征独特但可控。

靶向 PDPN 与 GD2 的新型 CAR-T 细胞组合以克服胶质母细胞瘤异质性

Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity.

这种新型 PDPN/GD2 CAR-T 细胞混合物在晚期临床前胶质母细胞瘤模型中显示出强效疗效，提示其具有治疗异质性胶质母细胞瘤和解决单抗原 CAR-T 细胞疗法相关局限性的潜力。